Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionBruker Corporation Common Stock (BRKR)
Fair value (2 models)
Not available
ACCE price target
$63.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Price used: $57.59 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
52
out of 100
Analysts
46% buy
13 covering
1-year return
+45.0%
Dividend yield
0.35%
Bruker Corporation Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Bruker makes scientific instruments, including NMR spectrometers, mass spectrometry systems and X-ray diffraction and elemental analysis equipment, sold mainly to pharmaceutical labs, academic research institutes and clinical customers. Its moat rests on installed-base instruments and service contracts that keep recurring revenue flowing, and on high switching costs once a lab validates its methods on a particular platform. Revenue growth of 5.2% is modest, but the 48.5% gross margin and 9.9% operating margin leave room for operating leverage if academic and pharma capital budgets firm up. The forward P/E of 13.8 sits well below the trailing P/E of zero (earnings currently negative), so the case depends on margin recovery being credible rather than on the headline earnings base. Negative ROE of -3.0% and no index membership mean the name is out of favour and warrants a closer look at cash flow and order trends before any conclusion.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Earnings collapse year over year
Earnings fell 81.8% year over year while revenue grew 5.2%, and the company posts a net margin of -2.0% with ROE at -3.0%. Profit is not converting from sales.
moderate
Thin free cash flow against debt
Free cash flow is only $14M against a debt-to-equity ratio of 0.83, leaving little cushion if earnings stay weak.
moderate
Heavy short interest
Short interest stands at 15.7% of the float, which signals meaningful bearish positioning and can add volatility around any news.
AI research notes
AI-assisted·How I use AIWritten Oct 19, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 11.6% a year on average over five years, showing the business has expanded steadily over time.
Free cash flow over the last twelve months was $14M, so the business still generates cash after its spending.
Latest quarterly earnings beat expectations, with earnings per share of 0.49 against 0.38 expected, a 28.9% surprise.
Why it could disappoint
Net margin is negative at -2.0%, meaning the company lost money on every dollar of revenue it recorded.
Return on invested capital of -0.2% shows the money put into the business is not currently earning a return.
Diluted share count rose 1.5% last fiscal year, so each shareholder's slice of the company shrank.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where BRKR's valuation models land
Price
$57.59
Model fair valueConfidence: low
about $65.98
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores